Lexaria Bioscience Corp. (LEXX) IPO - S-1 Filing, Stock & Insider Activity
Lexaria Bioscience Corp. IPO - Status & S-1 Filing
- Ticker: LEXX
- Status: Registered - S-1 filed with the SEC
- S-1 filed: 2025-12-05
- Exchange: NASDAQ
- Expected price range: not yet disclosed (set in a later S-1/A or pricing amendment)
- Shares offered: 2,760,000
- SEC CIK: 0001348362 · View the S-1 on SEC EDGAR →
Lexaria Bioscience Corp. is pre-IPO, so no insider Form 4 transactions have been filed yet. Once insiders begin reporting trades after the offering, they will appear on this page automatically.
Track every registration update on the InsiderAlpha IPO tracker.
Last SEC filing
Lexaria Bioscience Corp. (LEXX) - no SEC Form 4 insider filings recorded in the last 90 days. 9 Form 8-K material event filings were reported by LEXX in the last 90 days. InsiderAlpha tracks every LEXX SEC filing - Form 4, Form 144, and 8-K - in real time, including Rule 10b5-1 plan detection.
About Lexaria Bioscience Corp. (LEXX)
Lexaria Bioscience Corp. trades under the ticker LEXX. InsiderAlpha tracks 10 primary SEC Form 4 filings from 6 reporting insiders for LEXX since 2024, sourced directly from SEC EDGAR.
| Sector | Health Care insider trading |
|---|---|
| SIC classification | Pharmaceutical Preparations (SIC 2834) |
| SEC CIK | 0001348362 |
90-Day SEC Filing Activity
| Form 8-K filings (90d) | 9 |
|---|---|
| Latest Form 4 filing | 2026-03-18 |
Recent LEXX Insider Transactions (Form 4)
| Date | Insider | Role | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Christopher Bunka | Director | G - Bona-fide gift | 100.0K | $0.00 | - | SEC | |
| Christopher Bunka | Director | P - Open-market purchase | 11.9K | $0.91 | $11K | SEC | |
| Vanessa Carle | Secretary | P - Open-market purchase | 750 | $0.91 | $682 | SEC | |
| Christopher Bunka | Director | P - Open-market purchase | 15.6K | $0.92 | $14K | SEC | |
| John Martin Docherty | President CSO | P - Open-market purchase | 5.4K | $0.93 | $5K | SEC | |
| William Edward McKechnie | Director | P - Open-market purchase | 5.0K | $0.91 | $5K | SEC | |
| Richard Christopher | Chief Executive Officer | P - Open-market purchase | 15.0K | $0.91 | $14K | SEC | |
| Richard Christopher | Chief Executive Officer | P - Open-market purchase | 27.2K | $2.47 | $67K | SEC | |
| Richard Christopher | Chief Executive Officer | P - Open-market purchase | 22.8K | $2.24 | $51K | SEC |
All transactions sourced from SEC EDGAR Form 4 filings for Lexaria Bioscience Corp. (LEXX). Updated in real time as new filings are submitted to the SEC.
Recent LEXX Form 8-K Material Events
- - Other · neutral [SEC]
Trading halt (T3) for LEXX. LEXX - - Other · neutral [SEC]
Trading halt (T1) for LEXX. LEXX - - Other · neutral [SEC]
Trading halt (T1) for LEXX. LEXX - - Other · neutral [SEC]
Trading halt (T1) for LEXX. LEXX - - Other · neutral [SEC]
Trading halt (T1) for LEXX. LEXX
Recent Insider Filings
- - Christopher Bunka (Director)
- - Christopher Bunka (Director)
- - Richard Christopher (Chief Executive Officer)
- - William Edward McKechnie (Director)
- - John Martin Docherty (President CSO)
Form 4 Transaction Code Reference
SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in LEXX insider filings:
| P | Open-market purchase by the insider |
|---|---|
| S | Open-market sale by the insider |
| A | Grant, award, or other acquisition from the issuer |
| M | Exercise or conversion of derivative security (e.g. options) |
| F | Payment of exercise price or tax liability via share withholding |
| G | Bona-fide gift of securities |
| D | Disposition to the issuer (e.g. share buyback participation) |
| J | Other acquisition or disposition |
| X | Exercise of in-the-money or at-the-money derivative security |
| C | Conversion of derivative security |
| V | Transaction voluntarily reported earlier than required |
LEXX Insider Trading - FAQ
- What is the latest insider trade for LEXX?
- Lexaria Bioscience Corp. (LEXX) had 0 insider filings in the last 90 days, with the most recent on 2026-03-18. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
- How many insiders are buying LEXX stock?
- 0 insider purchases of LEXX were filed in the last 90 days.
- How many insiders are selling LEXX stock?
- 0 insider sales of LEXX were filed in the last 90 days.
- Where can I see LEXX SEC filings (Form 4, 10-K, 10-Q, 8-K)?
- This page tracks LEXX Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care Companies with Insider Activity
Other companies in the InsiderAlpha index with a significant SEC Form 4 insider-trading footprint:
- $LGVN Longeveron Inc.
- $LONA LeonaBio, Inc.
- $LRMR Larimar Therapeutics, Inc.
- $LTRN Lantern Pharma Inc.
- $LYEL Lyell Immunopharma, Inc.
- $MBX MBX Biosciences, Inc.
- $MDCX Medicus Pharma Ltd.
- $MDGL MADRIGAL PHARMACEUTICALS, INC.
- $MGRX MANGOCEUTICALS, INC.
- $MLYS Mineralys Therapeutics, Inc.
Related Companies - Recent Insider Activity
- UNITED THERAPEUTICS Corp (UTHR)
- Liquidia Corp (LQDA)
- BeOne Medicines Ltd. (ONC)
- PERRIGO Co plc (PRGO)
- Processa Pharmaceuticals, Inc. (PCSA)
- Nuvalent, Inc. (NUVL)
- CYTOKINETICS INC (CYTK)
- Elanco Animal Health Inc (ELAN)
- Avalo Therapeutics, Inc. (AVTX)
- NATURES SUNSHINE PRODUCTS INC (NATR)
Learn More
- What is SEC Form 4?
- How to read insider buying signals
- Rule 10b5-1 trading plans explained
- The cluster buying signal
Open the live LEXX dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.